Treating Post-inflammatory hyperpigmentation with a tyrosinase-inhibitor
Agneta Troilius Rubin, MD, PhD, is an Associate Professor in Dermatology, Malmö, Sweden; Zoi...
Read MoreFeb 23, 2022 | Aesthetic Feature | 0 |
Agneta Troilius Rubin, MD, PhD, is an Associate Professor in Dermatology, Malmö, Sweden; Zoi...
Read MoreSep 5, 2019 | Dermatology, Aesthetic Feature | 0 |
Dr Jennifer David discusses the use of cysteamine 5% as a novel first line non‑hydroquinone...
Read MoreSep 5, 2019 | Dermatology, Aesthetic Feature | 0 |
Mukta Sachdev, MD, and Ninon Patrao, MD, review the current ingredients making waves in...
Read MoreCavallini Maurizio and Papagni Marco discuss the use of a home-based treatment to potentiate the benefits of a previous chemical...
Read MoreJun 20, 2019 | Case Study | 0 |
Leonardo Marini, MD, PhD, discusses two recent cases of treating melasma in female patients with a new 5% cysteamine topical...
Read MoreJan 24, 2019 | Dermatology, Aesthetic Feature | 0 |
Sabine Zenker provides a review of the treatment principles for melasma using bleaching topicals...
Read MoreScientis Pharma, a leading dermatology research company based in Geneva, Switzerland, has released the world’s first cysteamine-based cream to treat...
Read MoreJul 22, 2016 | Dermatology, Aesthetic Feature | 1 |
Maurizio Ceccarelli examines how combination injections of hyaluronic and succinic acids can be used to treat hyperpigmentation and other skin...
Read More